이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

중등도에서 중증 활동성 크론병이 있는 소아 참가자를 대상으로 한 우스테키누맙 연구 (UNITI Jr)

2026년 7월 2일 업데이트: Janssen Research & Development, LLC

중등도에서 중증의 활동성 크론병을 앓고 있는 소아 참가자를 대상으로 공개 라벨 정맥 유도 치료 후 무작위 이중 맹검 피하 우스테키누맙 유지 관리로서 우스테키누맙의 효능, 안전성 및 약동학에 대한 3상 연구

이 연구의 목적은 임상적 관해 유도(글로벌) 및 임상적 관해 유지(US)에서 우스테키누맙 투약의 효능을 평가하는 것입니다. 중등도에서 중증의 활동성 크론병이 있는 소아 참가자의 안전성 프로파일 및 우스테키누맙 노출(약동학[PK])을 평가합니다.

연구 개요

상태

완전한

정황

개입 / 치료

연구 유형

중재적

등록 (실제)

101

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

      • Aachen, 독일, 52074
        • Universitätsklinikum Aachen
      • Berlin, 독일, 13353
        • Charite-Universitätsmedizin Berlin - Berlin
      • Essen, 독일, 45147
        • Universitätsklinikum Essen
      • Hanover, 독일, 30625
        • Medizinische Hochschule Hannover
      • Munich, 독일, 80337
        • Dr. von Haunersches Kinderspital
      • Regensburg, 독일, 93049
        • KUNO Klinik St. Hedwig
      • Ulm, 독일, 89075
        • Universitätsklinikum Ulm
      • Kazan', 러시아 제국, 420138
        • Kazan State Medical University
      • Moscow, 러시아 제국, 119571
        • Russian National Research Medical University named after N.I.Pirogov
      • Nizhny Novgorod, 러시아 제국, 603950
        • Privolzhsky Research Medical University of Ministry of Health of Russian Federation
      • Yaroslavl, 러시아 제국, 150032
        • Yaroslavl Regional Children's Clinical Hospital
    • Delaware
      • Wilmington, Delaware, 미국, 19803
        • Nemours DuPont Hospital for Children
    • Georgia
      • Atlanta, Georgia, 미국, 30342
        • Children's Center for Digestive Health Care
    • Minnesota
      • Rochester, Minnesota, 미국, 55905
        • Mayo Clinic
    • New Jersey
      • Morristown, New Jersey, 미국, 07962
        • Morristown Memorial Hospital
    • North Carolina
      • Charlotte, North Carolina, 미국, 28207
        • Levine Childrens at Atrium Health
    • Ohio
      • Cleveland, Ohio, 미국, 44106
        • University Hospitals Cleveland Medical Center
    • Pennsylvania
      • Hershey, Pennsylvania, 미국, 17033
        • Penn State Hershey Children's Hospital
    • Texas
      • Fort Worth, Texas, 미국, 76104
        • Cook Childrens Medical Center
    • Virginia
      • Fairfax, Virginia, 미국, 22031
        • Pediatric Specialists Of Virginia
      • Brussels, 벨기에, 1200
        • Cliniques Universitaires Saint Luc
      • Brussels, 벨기에, 1020
        • Universitair Kinderziekenhuis Koningin Fabiola
      • Ghent, 벨기에, 9000
        • UZ Gent
      • Jette, 벨기에, 1090
        • UZ Brussel
      • Leuven, 벨기에, 3000
        • UZ Leuven
      • Birmingham, 영국, B4 6NH
        • Birmingham Children's Hospital
      • Bristol, 영국, BS2 8BJ
        • University Hospitals Bristol and Weston NHS Foundation Trust
      • Cambridge, 영국, CB2 0QQ
        • Cambridge University Hospitals NHS Foundation Trust
      • Edinburgh, 영국, EH16 4TJ
        • Royal Hospital for Children and Young People
      • London, 영국, E1 2AT
        • Royal London Hospital
      • Be’er Ya‘aqov, 이스라엘, 70300
        • Yitzhak Shamir Medical Center
      • Haifa, 이스라엘, 34362
        • Carmel Medical Center
      • Jerusalem, 이스라엘, 9103102
        • Shaare Zedek Medical Center
      • Petah Tikva, 이스라엘, 4920235
        • Schneider Children's Medical Center
      • Bunkyō City, 일본, 113 8431
        • Juntendo University Hospital
      • Gunma, 일본, 371-0034
        • Gunma University Hospital
      • Ikoma, 일본, 630-0293
        • Kindai University Nara Hospital
      • Kurume, 일본, 830-0011
        • Kurume University Hospital
      • Saitama Shi, 일본, 330-8777
        • Saitama Childrens Medical Center
      • Sendai, 일본, 989-3126
        • Miyagi Children's Hospital
      • Setagaya Ku, 일본, 157 8535
        • National Center for Child Health and Development
      • Shimotsuke, 일본, 329-0498
        • Jichi Medical University Hospital
      • Tsu, 일본, 514 8507
        • Mie University Hospital
      • Gdansk, 폴란드, 80 803
        • Szpital im. M. Kopernika
      • Krakow, 폴란드, 30 663
        • Uniwersytecki Szpital Dzieciecy w Krakowie
      • Rzeszów, 폴란드, 35-302
        • Korczowski Bartosz Gabinet Lekarski
      • Warsaw, 폴란드, 04 501
        • WIP Warsaw IBD Point Profesor Kierkus
      • Warsaw, 폴란드, 04 730
        • Instytut Pomnik Centrum Zdrowia Dziecka
      • Budapest, 헝가리, 1083
        • Semmelweis Egyetem
      • Debrecen, 헝가리, 4032
        • Debreceni Egyetem Klinikai Kozpont
      • Miskolc, 헝가리, 3526
        • Borsod Abauj Zemplen Varmegyei Kozponti Korhaz es Egyetemi Oktato Korhaz
      • Nyíregyháza, 헝가리, 4400
        • Szabolcs Szatmár Bereg Vármegyei Oktatókórház
      • Szeged, 헝가리, 6720
        • Szegedi Tudományegyetem, Gyermekgyógyászati Klinika és Gyermekegészségügyi Centrum

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

2년 (어린이)

건강한 자원 봉사자를 받아들입니다

아니

설명

포함 기준:

  • 활동성 결장염, 회장염 또는 회장결장염을 동반한 크론병 또는 누공성 크론병이 과거에 내시경 및 조직학으로 확인된 경우
  • 중등도에서 중증의 활동성 크론병(기준선 소아 크론병 활동 지수[PCDAI] 점수가 [>] 30보다 큰 것으로 정의됨)이 있어야 합니다. 본 연구로 스크리닝하는 동안 궤양의 존재로 정의되는 활동성 크론병의 증거(크론병에 대한 단순 내시경 점수[SES-CD] 점수가 [>=] 3 이상임)와 함께 회장 대장내시경 검사를 받습니다. ileocolonoscopy 절차는 0주(유도 기간)에 연구 개입을 시행하기 전 약 3주 이내에 이루어져야 합니다. 0주차(유도 기간) 방문 전 3개월 이내에 녹화된 비디오 회장 대장경 검사는 회장 대장 내시경을 받았지만 다른 이유로 초기 선별에 실패한 참가자를 재검진하는 경우 사례별로 사용할 수 있습니다. 후원자와의 협의. 협착 또는 부적절한 창자 준비로 인해 궤양을 평가할 수 없는 경우 다음 기준 중 적어도 하나를 대신 적용할 수 있습니다. 스크리닝 시 [mg/L]) 또는; 스크리닝 시 >= 250mg/kg[mg/kg] 또는 >= 250μg/g[mcg/g]의 분변 칼프로텍틴
  • 경장 영양을 ​​받는 경우 유도 0주(I-0주) 이전 최소 2주 동안 안정적인 요법을 받아야 합니다.
  • 가임 여성은 스크리닝 시 및 연구 중재 투여 전 I-0주에 음성의 고감도 소변 임신 검사를 받아야 합니다.

제외 기준:

  • 증상이 있는 협착이나 협착, 단장 증후군 또는 수술이 필요할 것으로 예상되는 기타 징후와 같은 크론병 합병증이 있어 치료에 대한 반응을 평가하기 위해 PCDAI를 사용하지 못하거나 우스테키누맙 치료 효과
  • 잠복성 또는 활동성 육아종 감염, 히스토플라스마증 또는 콕시디오이드진균증의 병력이 있거나 스크리닝 이전에 비결핵 마이코박테리아 감염이 있었던 경우
  • 림프종을 포함한 림프증식성 질환의 존재 또는 병력을 포함하는 악성 종양의 존재 또는 병력, 또는 비정상적인 크기 또는 위치의 림프절병증(예: 목의 후삼각에 있는 결절, 쇄골하, 에피트로클리어, 또는 대동맥주위 부위), 의미가 불명확한 단클론성 감마글로불린병증, 또는 임상적으로 유의한 간비대 또는 비장비대
  • 중등도 또는 중증의 진행성 또는 조절되지 않는 간 또는 신장 기능 부전의 병력이 있습니다. 또는 중대한 심장, 혈관, 폐, 위장관, 내분비계, 신경계, 혈액계, 정신계(자살성향 포함) 또는 대사 장애
  • 연구 백신을 포함한 연구 개입을 받았거나 계획된 연구 개입의 첫 번째 투여 전 3개월 이내에 침습적 연구 의료 기기를 사용했거나 현재 조사 연구에 등록되어 있습니다. 코로나바이러스 질병 2019(COVID-19)에 대한 연구용 백신의 수령은 자동 제외 기준이 아닙니다.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: 오픈 라벨 우스테키누맙 정맥 주사(IV): 유도 기간
모든 참가자는 체표면적(BSA)(제곱미터당 밀리그램[mg/m^2]) 또는 체중 단계 유도 용량(킬로그램당 밀리그램)을 기준으로 유도 0주(I-0)에 우스테키누맙을 단일 IV 투여받습니다 [mg/kg]).
우스테키누맙은 유도 기간에 정맥 주사하고 유지 기간에 피하 투여합니다.
실험적: 우스테키누맙 피하(SC) 8주마다(q8w): 유지 기간
참가자는 유지 관리 주(주 M)-0, M-8, M-16, M-24에 BSA(mg/m^2) 또는 체중 단계별 유도 용량(mg/kg)에 따라 ustekinumab q8w의 SC 투여를 받습니다. , M 32 및 M-40 및 위약을 M-12 및 M-36주에 일치시켜 맹인을 유지합니다.
우스테키누맙은 유도 기간에 정맥 주사하고 유지 기간에 피하 투여합니다.
일치하는 위약은 SC 주사로 투여됩니다.
실험적: 우스테키누맙 SC 12주마다(q12w): 유지 기간
참가자는 M-0, M-12, M-24, M-36주에 BSA(mg/m^2) 또는 체중 단계 유도 용량(mg/kg)에 기초한 ustekinumab q12w의 SC 투여와 일치하는 위약을 다음 주에 받게 됩니다. 맹인을 유지하기 위한 M-8, M-16, M-32 및 M-40주.
우스테키누맙은 유도 기간에 정맥 주사하고 유지 기간에 피하 투여합니다.
일치하는 위약은 SC 주사로 투여됩니다.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Global Outcome Measure: Percentage of Participants With Clinical Remission at Induction Week 8 (Week I-8)
기간: Induction Week 8 (Week I-8)
Clinical remission was defined as a Pediatric Crohn's Disease Activity Index (PCDAI) score <=10. The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency, and general well-being); laboratory scores (3 items: hematocrit [HCT], erythrocyte sedimentation rate [ESR], Albumin); growth scores (2 items: weight and height); physical examination scores (2 items: abdomen and perirectal disease); and extraintestinal manifestations. The category of severity for each index item is assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality. For hematocrit and erythrocyte SR, the maximum score =5. For albumin level, the maximum score = 10. All items were summed to derive the total score. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Induction Week 8 (Week I-8)
US-specific Outcome Measure: Percentage of Participants With Clinical Remission at Maintenance Week 44
기간: Maintenance Week 44 (Study Week 52)
Clinical remission was defined as a Pediatric Crohn's Disease Activity Index (PCDAI) score <=10. The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency, and general well-being); laboratory scores (3 items: HCT, ESR, Albumin); growth scores (2 items: weight and height); physical examination scores (2 items: abdomen and perirectal disease); and extraintestinal manifestations. The category of severity for each index item was assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality. For hematocrit and erythrocyte SR, the maximum score= 5. For albumin level, the maximum score= 10. All items were summed to derive the total score. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
기간: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with TEAEs were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE did not necessarily have a causal relationship with the intervention. TEAEs were defined as AEs occurring at or after the initial administration of the study intervention.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)
기간: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with TESAEs was reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE did not necessarily have a causal relationship with the intervention. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; or congenital anomaly. TESAEs were defined as any SAE occurring at or after the initial administration of the study intervention.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With AEs Leading to Discontinuation of Study Intervention
기간: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 40 (Study Week 48)
Number of participants with AEs leading to discontinuation of study intervention were reported.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 40 (Study Week 48)
Global and US-specific Outcome Measures: Number of Participants With AEs of Special Interest (AESI)
기간: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE did not necessarily have a causal relationship with the intervention. AESI were defined as any newly identified malignancy, or case of active TB, or opportunistic infection occurring after the first administration of study intervention.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology
기간: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with abnormalities in clinical laboratory parameters (hematology) were reported. It included hemoglobin (Hb). Grades 0-4 were based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), where Grade 0 was normal, Grade 1 was mild, Grade 2 was moderate, Grade 3 was severe or medically significant but not immediately life-threatening, and Grade 4 was life-threatening consequences. Higher grades showed more severe abnormalities. Only abnormalities where atleast one participant had data are reported. Inc = increased, Dec= decreased.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Abnormalities in Clinical Laboratory Parameters: Chemistry
기간: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with abnormalities in clinical laboratory parameters were reported. It included chemistry measures: alanine aminotransferase (ALT), aspartate aminotransferase (AST),blood bilirubin (BB). Grades 0-4 were based on NCI-CTCAE version 5.0, where Grade 0 was Normal, Grade 1 was mild, Grade 2 was moderate, Grade 3 was severe or medically significant but not immediately life-threatening, and Grade 4 was life-threatening consequences. Higher grades showed more severe abnormalities. Only abnormalities where at least one participant had data are reported. Inc = increased, Dec= decreased.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Reactions Temporally Associated With Intravenous (IV) Infusion (Induction Period) and Subcutaneous (SC) Injection-Site Reactions (Maintenance Period)
기간: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with reactions temporally associated with intravenous (IV) infusion (Induction Period) and subcutaneous (SC) Injection-Site Reactions (Maintenance Period) were reported.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Serum Ustekinumab Concentrations
기간: Induction Period: Week 0 (Pre-infusion), Week I-0 (1-hour post infusion), Week I-3, Week I-6, and Week I-8; Maintenance Period: Week M-4, Week M-8, Week M-12, Week M-16, Week M-24, Week M-32, Week M-36 and Week M-44
Serum ustekinumab concentrations were reported.
Induction Period: Week 0 (Pre-infusion), Week I-0 (1-hour post infusion), Week I-3, Week I-6, and Week I-8; Maintenance Period: Week M-4, Week M-8, Week M-12, Week M-16, Week M-24, Week M-32, Week M-36 and Week M-44

2차 결과 측정

결과 측정
측정값 설명
기간
Global Outcome Measure: Percentage of Participants With Clinical Remission at Induction Week 6 as Assessed by Short Pediatric Crohn's Disease Activity Index (sPCDAI)
기간: Induction Week 6 (Week I-6)
Clinical remission was defined as a short Pediatric Crohn's Disease Activity Index (sPCDAI) score <=10. The sPCDAI was composed of six components: abdominal pain, stool frequency, patient general well-being, body weight, abdominal examination (abdominal mass and tenderness), and extraintestinal manifestations. Each component was assigned a score of 0, 5, 10, or 20, depending on the severity of findings, with higher scores indicating greater disease activity, while lower scores (closer to 0) reflected clinical remission or minimal disease activity. Individual component scores were summed to derive the total sPCDAI score, which ranged from 0 to 90. Higher score indicate greater severity. The sPCDAI score was calculated only when >=3 of the 6 components were available.
Induction Week 6 (Week I-6)
Global Outcome Measure: Percentage of Participants With Clinical Response at Induction Week 8
기간: Induction Week 8
Assessment of response in children with Crohn's disease was evaluated using the PCDAI. Clinical response was defined as a reduction from baseline of >=12.5 points in the PCDAI score, calculated by summing weighted scores from 11 items across five domains: symptom history (abdominal pain, stool frequency, and general well-being); laboratory scores (hematocrit, erythrocyte sedimentation rate, and albumin); growth scores (weight and height); physical examination scores (abdominal and perirectal disease); and extraintestinal manifestations. Each index item was assigned a severity score of 0 (normal), 5 (mild abnormality), or 10 (severe abnormality). For HCT and ESR, maximum score was 5, and for albumin level, maximum score was 10. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity. Lower PCDAI scores reflected lower disease activity, with a resulting score of <=30 on the 0-100 scale.
Induction Week 8
Global and US-specific Outcome Measures: Percentage of Participants With Clinical Response at Induction Week 6 as Assessed by sPCDAI
기간: Induction Week 6
sPCDAI clinical response was defined as reduction from baseline in the sPCDAI score of >=10. The 6-item sPCDAI score ranges from 0 (no disease activity) to 90 (severe disease activity),calculated by summing weighted scores for abdominal pain, stool frequency, general well-being, body weight, abdominal exam, and extraintestinal manifestations. Each component was assigned a score of 0, 5, 10, or 20, depending on the severity of findings, with higher scores indicating greater disease activity, while lower scores (closer to 0) reflected minimal disease activity. Individual component scores were summed to derive the total sPCDAI score, which ranged from 0 to 90. Higher score indicate greater severity. The sPCDAI score was only calculated when >=3 of the 6 components were available.
Induction Week 6
Global Outcome Measure: Percentage of Participants With Endoscopic Response at Maintenance Week 8 as Assessed by Simplified Endoscopic Score-Crohn's Disease (SES-CD)
기간: Maintenance Period Week 8 (Study Week 16)
Endoscopic response was assessed using the Simplified Endoscopic Activity Score for Crohn's Disease (SES-CD), a validated endoscopic scoring system based on four components: size of ulcers, extent of ulcerated surface, extent of affected surface, and presence of narrowing. Each component was scored from 0 to 3 across five intestinal sections: ileum, right colon, transverse colon, left (descending and sigmoid) colon, and rectum. Component scores were summed across all sections to derive a total SES-CD score ranging from 0 to 56, with higher scores indicating greater endoscopic disease severity. Endoscopic response was defined as a >=50% reduction from baseline in SES-CD score or achievement of an SES-CD score <=2 in participants with a baseline SES-CD score >=3.
Maintenance Period Week 8 (Study Week 16)
Global Outcome Measure: Percentage of Participants With Clinical Response at Maintenance Week 8
기간: Maintenance Week 8 (Study Week 16)
Clinical response was defined as a reduction from baseline of >=12.5 points in PCDAI score, calculated by summing weighted scores from 11 items across five domains: symptom history(abdominal pain, stool frequency, and general well-being); laboratory scores (hematocrit, erythrocyte sedimentation rate, and albumin); growth scores(weight and height); physical examination scores(abdominal and perirectal disease); extraintestinal manifestations. Each index item was assigned a severity score of 0(normal), 5(mild abnormality), or 10(severe abnormality). For HCT and ESR, maximum score was 5, for albumin level, maximum score was 10. Total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity. Lower PCDAI scores reflected lower disease activity, with resulting score of <=30 on 0-100 scale.
Maintenance Week 8 (Study Week 16)
Global and US-specific Outcome Measures: Percentage of Participants With Endoscopic Response at Maintenance Week 44 as Assessed by SES-CD
기간: Maintenance Week 44 (Study Week 52)
Endoscopic response was assessed using the Simplified Endoscopic Activity Score for Crohn's Disease (SES-CD), a validated endoscopic scoring system based on four components: size of ulcers, extent of ulcerated surface, extent of affected surface, and presence of narrowing. Each component was scored from 0 to 3 across five intestinal sections: ileum, right colon, transverse colon, left (descending and sigmoid) colon, and rectum. Component scores were summed across all sections to derive a total SES-CD score ranging from 0 to 56, with higher scores indicating greater endoscopic disease severity. Endoscopic response was defined as a >=50% reduction from baseline in SES-CD score or achievement of an SES-CD score <=2 in participants with a baseline SES-CD score >=3.
Maintenance Week 44 (Study Week 52)
US-specific Outcome Measure: Percentage of Participants With Clinical Response at Maintenance Week 44
기간: Maintenance Week 44 (Study Week 52)
Clinical response was defined as a reduction from baseline of >=12.5 points in PCDAI score, calculated by summing weighted scores from 11 items across five domains: symptom history(abdominal pain, stool frequency, and general well-being); laboratory scores (hematocrit, erythrocyte sedimentation rate, and albumin); growth scores(weight and height); physical examination scores(abdominal and perirectal disease); extraintestinal manifestations. Each index item was assigned a severity score of 0(normal), 5(mild abnormality), or 10(severe abnormality). For HCT and ESR, maximum score was 5, for albumin level, maximum score was 10. Total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity. Lower PCDAI scores reflected lower disease activity, with resulting score of <=30 on 0-100 scale.
Maintenance Week 44 (Study Week 52)
US-specific Outcome Measure: Percentage of Participants With Corticosteroid-free Clinical Remission at Maintenance Week 44
기간: Maintenance Period Week 44 (Study Week 52)
Corticosteroid-free remission was defined as PCDAI score of <=10 points and not receiving corticosteroids for at least 90 days prior to Week M-44. The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency; and general well-being); laboratory scores (3 items: HCT, ESR, Albumin); growth scores (2 items: weight and height), physical examination scores (2 items: abdomen and perirectal disease), and extraintestinal manifestations. The category of severity for each index item was assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality. For hematocrit and erythrocyte SR, the maximum score= 5. For albumin level, the maximum score= 10. All items were summed to derive the total score. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Maintenance Period Week 44 (Study Week 52)
Global Outcome Measure: Percentage of Participants With Clinical Remission at Maintenance Week 44 Who Had Clinical Remission at Induction Week 8
기간: Maintenance Week 44 (Study Week 52)
Clinical remission was defined as Pediatric Crohn's Disease Activity Index (PCDAI) score <=10. The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency; and general well-being); laboratory scores (3 items: HCT, ESR, Albumin); growth scores (2 items: weight and height), physical examination scores (2 items: abdomen and perirectal disease), and extraintestinal manifestations. The category of severity for each index item was assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality. For hematocrit and erythrocyte SR, the maximum score= 5. For albumin level, the maximum score= 10. All items were summed to derive the total score. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Maintenance Week 44 (Study Week 52)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 책임자: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2021년 4월 6일

기본 완료 (실제)

2024년 11월 28일

연구 완료 (실제)

2025년 3월 3일

연구 등록 날짜

최초 제출

2020년 12월 14일

QC 기준을 충족하는 최초 제출

2020년 12월 14일

처음 게시됨 (실제)

2020년 12월 17일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 7월 30일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 7월 2일

마지막으로 확인됨

2026년 7월 1일

추가 정보

이 연구와 관련된 용어

키워드

기타 연구 ID 번호

  • CR108864
  • 2019-004225-24 (EudraCT 번호)
  • CNTO1275CRD3004 (기타 식별자: Janssen Research & Development, LLC)
  • 2023-504978-38-00 (레지스트리 식별자: EUCT number)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Johnson & Johnson의 Janssen 제약 회사의 데이터 공유 정책은 www.janssen.com/clinical-trials/transparency에서 확인할 수 있습니다. 이 사이트에 명시된 바와 같이 연구 데이터에 대한 액세스 요청은 Yale Open Data Access(YODA) 프로젝트 사이트(yoda.yale.edu)를 통해 제출할 수 있습니다.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .